stockrowBaxter International Inc.
BAX Healthcare Medical Instruments & Supplies
Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024.
- Revenue
- +4.97%
- EPS
- +731.9%
- Free cash flow
- +255.6%
- Total debt
- −9.48%
Quarter to September 2026, against a year earlier
Follow BAX
Alert me
Baxter International Inc. (BAX) Return on equity
Baxter International Inc.'s return on equity over the twelve months to 30 September 2026 was −10.6%, up 4.0 percentage points from fiscal 2025 (−14.6%). Over the past ten years it has ranged from −32.4% (fiscal 2022) to 57.9% (fiscal 2016); the current reading is higher than 18% of that period. That is below the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −14.6% | (6.20) |
| FY2024 | −8.38% | (45.36) |
| FY2023 | 37.0% | 69.39 |
| FY2022 | −32.4% | (46.80) |
| FY2021 | 14.4% | 1.14 |
| FY2020 | 13.3% | 0.56 |
| FY2019 | 12.7% | (5.52) |
| FY2018 | 18.2% | 11.29 |
| FY2017 | 6.92% | (51.00) |
| FY2016 | 57.9% | 46.55 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| WST West Pharmaceutical Services, Inc. compare | 21.2% |
| ATR AptarGroup, Inc. compare | 9.86% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| AVTR Avantor, Inc. compare | 5.91% |
| SOLV Solventum Corporation compare | 3.19% |
| ALGN Align Technology, Inc. compare | 0.00% |
| RGEN Repligen Corporation compare | −0.57% |
| BLCO Bausch + Lomb Corporation compare | −1.71% |
| BAX Baxter International Inc. | −10.6% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BAX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement